Sentences with phrase «of allogeneic stem cell»

Not exact matches

In the study, analysis of patient samples demonstrated that high LSC17 scores meant poor outcomes with current standard treatment, even for patients who had undergone allogeneic stem cell transplantation.

Of these 34 patients, 13 (38 %) have remained in remission for five years, and an additional two patients whose disease did not progress after BV went on to achieve remission after receiving allogeneic stem cell transplant (in which healthy stem cells are taken from a donor and administered to the patient).

As a result, they are currently being investigated as a cellular therapeutic for the treatment of autoimmune diseases and long - term patient and graft survival following solid organ transplantation, and allogeneic hematopoietic stem cell transplantation.

Sioud M, Mobergslien A, Boudabous A, Fløisand Y. Evidence for the involvement of galectin - 3 in mesenchymal stem cell suppression of allogeneic T - cell proliferation.

Mehta J, Gordon LI, Tallman MS, et al., Does younger donor age affect the outcome of reduced - intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?

Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals.

Allogeneic Sibling Donor Peripheral Blood Stem Cells Transplantation With Myeloablative Conditioning for Chronic Myeloid Leukemia in Blast Crisis - Successful Treatment Despite Severe Phase of the Disease

In close collaboration with universities and physicians world - wide, our comprehensive investigational stem cell treatments employ well - targeted combinations of allogeneic human umbilical cord stem cells, autologous bone marrow stem cells, and autologous adipose stem cells for the diseases listed below.

Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS - IH).

Horwitz et al 79 reported that donor MSC contributed to bone remodelling after allogeneic stem cell transplantation (SCT) in 3 children with osteogenesis imperfecta, a rare genetic disorder of type I collagen.

One promising solution to increase long - term overall survival has been in the area of allogeneic hematopoietic stem cell transplantation (HCST).

In the future, outpatient blood and bone marrow stem cell transplantation will be offered to a broader group of patients with other blood disorders and for allogeneic transplants (transplant from non-twin donor stem cells).

Use of a lower dose of rabbit anti — T - lymphocyte globulin (ATLG) was superior to a higher dose in children with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation (HSCT) from an unrelated donor, according to the results of a study published in Lancet Oncology.

Allogeneic stem cell transplantation to leukaemic patients, in which the patient's own diseased bone marrow is replaced by healthy donor material, is one of the best - established and most effective immunological therapies.

Allogeneic cell therapies involving primary cell types such as bone marrow mesenchymal stromal / stem cells (BM - MSCs), hematopoietic stem and progenitor cells (HSPCs), and T and natural killer (NK) cells for immunotherapy applications are especially challenging because of the vigorous process of screening...

• Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤ 1.5 times ULN) • Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN Exclusion Criteria: • Presence of active / uncontrolled central nervous system involvement • History of clinically significant cardiac disease; uncontrolled hypertension • Left ventricular ejection fraction (LVEF) < 45 % • Allogeneic stem cell transplant within 100 days before first dose of study drug • Known history of human immunodeficiency virus (HIV) infection • Chronic or active hepatitis B or C, requiring antiviral therapy • Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study • Serious, uncontrolled infection • Unresolved chronic toxicity > grade 1 from prior therapy • Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of the study

Patients receive one of two types of stem cell - based transplants: autologous, in which a patient donates and receives back his / her own stem cells; or allogeneic, in which bone marrow - derived stem cells come from a related or unrelated donor whose human leukocyte antigens (HLA) are genetically matched with those of a patient.

Low - Dose ATLG Prevents GVHD in Pediatric Hematologic Malignancies: A newly published randomized phase III study of pediatric patients showed lower doses of rabbit anti — T - lymphocyte globulin (ATLG) was superior to a higher dose in children with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation from an unrelated donor.

Ponatinib Extends Survival Over Transplant in Chronic Phase CML: The results of a new study that included patients from the PACE trial and the European Bone Marrow Transplant registry revealed that treatment with ponatinib yielded better overall survival (OS) compared with allogeneic stem cell transplantation (allo - SCT) in patients with chronic phase chronic myeloid leukemia (CP - CML) with a T315I mutation.

Burmeister DM, Stone R, Wrice N, et al., Delivery of Allogeneic Adipose Stem Cells in Polyethylene Glycol ‐ Fibrin Hydrogels as an Adjunct to Meshed Autografts After Sharp Debridement of Deep Partial Thickness Burns.

If these results are confirmed and one or more of these FLT3 - targeted drugs become approved by the FDA, testing for the FLT3 biomarker may eliminate the need for thousands of patients to undergo stem cell transplantation (each allogeneic transplant costs hundreds of thousands of dollars and place recipients at grave risk of infection and other complications such as Graft vs. Host disease).

Review of «Delivery of Allogeneic Adipose Stem Cells in PEG - Fibrin Hydrogels as an Adjunct to Meshed Autografts After Sharp Debridement of Deep Partial Thickness Burns» from STEM CELLS Translational Medicine by Stuart P. AtkiStem Cells in PEG - Fibrin Hydrogels as an Adjunct to Meshed Autografts After Sharp Debridement of Deep Partial Thickness Burns» from STEM CELLS Translational Medicine by Stuart P. AtkCells in PEG - Fibrin Hydrogels as an Adjunct to Meshed Autografts After Sharp Debridement of Deep Partial Thickness Burns» from STEM CELLS Translational Medicine by Stuart P. AtkiSTEM CELLS Translational Medicine by Stuart P. AtkCELLS Translational Medicine by Stuart P. Atkinson

He established the Long Term Transplant Clinic at Vanderbilt in 2006, which allows for systematic multidisciplinary follow up of patients after allogeneic stem cell transplant.

Thus, one can transplant fully allogeneic hematopoietic stem cells and co-transplant, for example, hearts from the hematopoietic stem cell donor to induce lifelong donor - specific acceptance of the transplant, without deleterious immunosuppression [4].

Acute myeloid leukemia (AML) is the leading cause of leukemia mortality in the United States.1 Curative treatment involves intensive induction chemotherapy, before proceeding to either consolidation chemotherapy or allogeneic stem cell transplantation based on the patient's risk for relapse.2 This approach has been employed for > 4 decades and, although most individuals achieve complete remissions with front - line therapy, 3 the majority of patients ultimately relapse with drug - resistant disease, and overall survival rates remain disappointingly poor.4 The limited ability of many patients to tolerate the intense chemotherapy - based treatments, in particular hematological toxicity, further contributes to the poor outcomes noted in this disease.

Macmillan, 2014; Holler, E., et al. «Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: Loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft - versus - host disease.»